Clinical trials: Uveitis
Non-infectious Anterior Uveitis, Uveitic Glaucoma
TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma
- Trial name
- NCT05042609
- Testing
- TRS01, FDA approved steroid eye drop (masked)
- Where
- 30 sites in United States, France and 1 more
- Volunteers
- 142 people
- Sponsor
- Tarsier Pharma
Uveitis
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear…
- Trial name
- NCT04088409
- Testing
- Baricitinib, Adalimumab
- Where
- 20 sites in France, Germany and 3 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Non-infectious Uveitis Affecting the Posterior Segment of the Eye
Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
The main aim is to test how safe and effective the medicine ILUVIEN® (190μg) is for children and adolescents, who have non-infectious uveitis that keeps coming back and affects the back of the eye.
- Trial name
- NCT06539481
- Testing
- fluocinolone acetonide 190 micrograms
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Uveitis
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
- Trial name
- NCT02916017
- Where
- 39 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Inflammation, Uveitis
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Investigate the impact of the Fluocinolone Acetonide (FA) intravitreal implants
- Trial name
- NCT01060787
- Testing
- Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Bausch & Lomb Incorporated
Uveitis, Posterior
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant
- Trial name
- NCT03145025
- Testing
- Retisert, Fluocinolone Acetonide Intravitreal Implant
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Anterior Uveitis
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- EGP-437-006 (NCT02517619)
- Testing
- Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Anterior Uveitis
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- NCT01505088
- Testing
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution
- Where
- 39 sites in United States
- Volunteers
- 193 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Endogenous Anterior Uveitis
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.
- Trial name
- NCT01201798
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404612)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 218 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis, Anterior, Panuveitis
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
- Trial name
- LUMINATE (NCT00404885)
- Testing
- LX211
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 108 people
- Sponsor
- Lux Biosciences, Inc.
Noninfectious Posterior Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants
This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the…
- Trial name
- NCT00407082
- Testing
- fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Bausch & Lomb Incorporated
Non-infectious Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant
This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide intravitreal implants for the management of subjects with non-infectious uveitis affecting the…
- Trial name
- NCT00456482
- Testing
- Fluocinolone Acetonide 0.59mg, Fluocinolone Acetonide 2.1mg
- Volunteers
- 239 people
- Sponsor
- Bausch & Lomb Incorporated
Non-infectious Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy
This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and efficacy study. The aim of this study is to evaluate the effect of an intravitreal fluocinolone acetonide (0.59 mg) implant compared to…
- Trial name
- NCT00468871
- Testing
- fluocinolone acetonide intravitreal implant, corticosteroids and immunosuppressants
- Volunteers
- 140 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetes, Macular Edema
Research Study in Patients With Persistent Macular Edema
The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods.
- Conditions
- Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease
- Trial name
- NCT00035906
- Testing
- DEX PS DDS®
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Uveitis, Anterior
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment…
- Trial name
- NCT00694135
- Testing
- EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
- Where
- 19 sites in United States, India
- Volunteers
- 40 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Non-infectious Uveitis
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis
The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.
- Trial name
- BSX-003 (NCT00646425)
- Testing
- Basiliximab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cerimon Pharmaceuticals
Uveitis
Study of Difluprednate in the Treatment of Uveitis
The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.
- Trial name
- NCT00501579
- Testing
- Difluprednate, Prednisolone Acetate
- Where
- United States
- Sponsor
- Sirion Therapeutics, Inc.
Anterior Uveitis, Panuveitis
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.
- Trial name
- NCT00406887
- Testing
- Difluprednate Ophthalmic Emulsion
- Volunteers
- 140 people
- Sponsor
- Sirion Therapeutics, Inc.